Microdosing Semaglutide Rx
A low dose GLP-1 approach designed to work in sync with your body, which may support moderate weight loss and cravings while minimizing side effects.
- Monthly, 2-mo, and 4-mo plans
- Starting price applies to 4-mo plans
- US-licensed pharmacies
- Pause or cancel anytime
Frequently asked questions
Microdosing Semaglutide uses lower amounts than standard dosing. Your provider will guide your plan and help you understand how to measure your dose correctly. The goal is the lowest dose that delivers benefits while minimizing side effects, not the highest dose you can manage.
Yes. If your goals change or you need more support, your provider can help determine whether a full-dose GLP-1 prescription may be a better fit.
No. Microdosing Semaglutide uses lower amounts than standard GLP-1 dosing and is designed for adults seeking a gentler, clinician-guided approach.
Microdosing Semaglutide is self-administered according to your provider-guided titration schedule. If prescribed, a US-licensed provider will provide a tailored dosage schedule and specific treatment instructions with your care plan.
Important safety information and common side effects
Microdosing Semaglutide medication may include glycine, an amino acid intended to support cellular function and metabolism.
Do not use with other GLP-1 receptor agonist medications, or any other products containing GLP-1s.
Side effects
Microdosing GLP-1 is a low dose injectable GLP-1 prescription (Tirzepatide or Semaglutide).
Compounded GLP-1s have not been evaluated by the FDA, but side effects are expected to be similar to other GLP-1-based medications reviewed by the FDA, which have the following side effects: nausea, diarrhea, vomiting, constipation, abdominal (stomach) pain, headache, fatigue, dyspepsia (indigestion), dizziness, abdominal distension, eructation (belching), hypoglycemia (low blood sugar), flatulence (gas buildup), gastroenteritis (an intestinal infection), and gastroesophageal reflux disease (a type of digestive disorder).
Common side effects normally go away on their own within a few days or up to 2-3 weeks. Read our blog for more tips on how to manage GLP-1 side effects. If you find that any side effects persist for longer than this or get worse over time, stop taking your medication and contact your provider as soon as possible. For a full list of side effects, please review the Mayo Clinic’s Semaglutide and Tirzepatide resources.
Other important safety information
Do not use GLP-1s if you have a personal or family history of medullary thyroid carcinoma (MTC), multiple endocrine neoplasia syndrome 2 (MEN2), or pancreatitis.
Do not use GLP-1s if you are pregnant or breastfeeding, or planning to become pregnant or breastfeed.
Though rare, allergic reactions to GLP-1 medications are possible. If you notice any shortness of breath or swelling around your face, tongue, or throat after using GLP-1s, stop using the medication immediately and contact emergency services right away.
As with any prescription medicine, the dose prescribed is for you and you alone. Do not, under any circumstances, allow anyone else to use your prescription.
Tell your healthcare provider about all the medications you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Tell your healthcare provider if you are taking any medications to treat diabetes, including sylfonylureas or insulin.
Note: The above statements have not been evaluated by the Food and Drug Administration. This product alone is not intended to diagnose, treat, cure, or prevent any disease. Please consult a medical professional to determine whether or not Microdosing Semaglutide is appropriate for you.
Disclaimer
What is Microdosing Semaglutide?
(sem-uh-GLOO-tide)Not everyone needs full doses of GLP-1. Microdosing Semaglutide uses smaller doses than standard GLP-1 dosing, designed to work in sync with the body instead of flooding it all at once.
For those who want support with moderate weight goals, appetite, and food noise, Microdosing may offer a lower-dose way to begin GLP-1 care without extremes.1 2 3
10 lbs average weight loss by 6 months
How Microdosing Semaglutide works
1 Month
3 Months
6 Months
1 Year and Beyond
Our GLP-1 research is shaping what comes next
We’re running one of the first longevity-focused clinical trials on GLP-1 microdosing, led by our Stanford PhD-led Research Team. With a fully in-house care team, longevity researchers, and 40+ science-backed protocols, we’re built to support the bigger picture of your health.
GLP-1 care that starts with you
$99/month
Applies to 4-month plan billed in full ($159/mo after)
What’s included
-
Personalized, clinician-guided plan
-
Monthly, 2-month, and 4-month plans
-
Dispensed by US-licensed compounding pharmacy
-
Unlimited protocol adjustments and messaging
-
Ongoing support and check-ins
-
Pause or cancel anytime
-
Backed by our in-house Stanford PhD-led team
Clinically studied
The science of Microdosing GLP-1
In a series of studies, low doses of GLP-1 receptor agonists were shown to modulate inflammatory pathways, support mitochondrial function, and lower risk factors for cognitive decline in study participants—giving Microdosing GLP-1 promising potential for extending healthspan.5 7 8
Choosing how you age starts here
Connect with a clinician
Get your discreet shipment
Receive continuous support
Disclaimer
Weight, personalized.
Frequently asked questions
Semaglutide works with the GLP-1 pathway, which is involved in appetite, fullness, food intake, and metabolic response.⁶ Microdosing uses lower amounts than standard dosing, with provider-guided adjustments over time.
Microdosing Semaglutide may be a fit for those seeking moderate weight support, help with appetite or food noise, or a gentler way to begin GLP-1 care.¹ ² ³
Microdosing is not designed to match full-dose GLP-1 weight loss. Full-dose GLP-1s are dosed to maximize weight loss; microdosing is dosed to find the minimum amount that may deliver metabolic and craving-related benefits while minimizing side effects. It’s intended for people seeking a lower-dose approach for moderate weight loss and more long-term health goals.
At full doses, Semaglutide acts on a single pathway, GLP-1, and has the longer track record, including a large trial showing meaningful cardiovascular risk reduction. Tirzepatide acts on two pathways, GLP-1 and GIP, and tends to produce somewhat greater appetite suppression at comparable standard doses.⁹
Microdosing Semaglutide is typically taken once weekly by subcutaneous injection, only as prescribed by your provider. If approved you will receive a personalized dosing schedule based on your health history and goals.